UC-Davis plans revamp of teaching hospital complex American Veterinary Medical Association In 1970, the University of California-Davis School of Veterinary Medicine opened the doors to its $6 million Veterinary Medical Teaching. |
Follow this link:
UC-Davis plans revamp of teaching hospital complex - American Veterinary Medical Association
Research Corridor has published a new research study titled Canine Stem Cell Therapy Market Growth, Share, Opportunities, Competitive Analysis and Forecast, 2017 2025. The Canine Stem Cell Therapy market report studies current as well as future aspects of the Canine Stem Cell Therapy Market based upon factors such as market dynamics, key ongoing trends and segmentation analysis. Apart from the above elements, the Canine Stem Cell Therapy Market research report provides a 360-degree view of the Canine Stem Cell Therapy industry with geographic segmentation, statistical forecast and the competitive landscape.
Browse the complete report at http://www.researchcorridor.com/canine-stem-cell-therapy-market/
Geographically, the Canine Stem Cell Therapy Market report comprises dedicated sections centering on the regional market revenue and trends. The Canine Stem Cell Therapy market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific and Rest of the World (RoW). The RoW segment consists Latin America and the Middle East & Africa. The Canine Stem Cell Therapy market has been extensively analyzed on the basis of various regional factors such as demographics, gross domestic product (GDP), inflation rate, acceptance and others. Canine Stem Cell Therapy Market estimates have also been provided for the historical years 2015 & 2016 along with forecast for the period from 2017 2025.
The research report also provides a comprehensive understanding of Canine Stem Cell Therapy market positioning of the major players wherein key strategies adopted by leading players has been discussed. The Canine Stem Cell Therapy industry report concludes with the Company Profiles section which includes information on major developments, strategic moves and financials of the key players operating in Canine Stem Cell Therapy market.
Key Takeaways:
Market Dynamics in the Canine Stem Cell Therapy Market
Key Ongoing Regional Trends
Canine Stem Cell Therapy Market Estimates for Years 2014 2025
Canine Stem Cell Therapy Market Positioning of Key Players
Key Strategies Adopted by the Leading Players
Attractive Investment Proposition
Canine Stem Cell Therapy Market Inclination Insights
Related Reports
About Research Corridor
Research Corridor provides End to End Solution for Market Research Consulting and Custom Research Reports. Database of Over 42000 Global Market Reports Research Corridor is world leading company in syndicated market Research Reports.
For More Information, Visit Research Corridor
Media ContactCompany Name: Research CorridorContact Person: VikramEmail: sales@researchcorridor.com
See the original post:
Canine Stem Cell Therapy Market Research Report Now Available at Research Corridor - Thrasher Backer
Twiga, a 14-year-old female giraffe with advanced arthritis and osteoporosis in her feet, was fitted with custom shoes. (Photo courtesy of the Cheyenne Mountain Zoo.)
Cheyenne Mountain Zoo appears to have made medical history with its innovative giraffe treatments.
Mahali, a 14-year-old male giraffe who suffered from chronic lameness, is believed to be the first in the world to be injected with stem cells grown from giraffe blood, according to a news release from the zoo.
Stem cell therapy was chosen in the treatments led by Dr. Liza Dadone, the zoo's head veterinarian, because it has proven to repair damaged tissue. Staff at Colorado State University's James L. Voss Veterinary Teaching Hospital in Fort Collins helped with the treatment.
Nearly a month after the procedure, when Mahali was injected with about 100 million stem cells, thermographic images of the giraffe's front legs show "a considerable decline" in inflammation in his front left leg, the leg that had been giving him trouble, the zoo said.
"This is meaningful to us not only because it is the first time a giraffe has been treated with stem cells, but especially because it is bringing Mahali some arthritis relief and could help other giraffes in the near future," Dadone said in a written statement.
Dadone said it's not clear whether the successful results are due only to the stem cell treatment or a combination of treatments.
"Prior to the procedure, he was favoring his left front leg and would lift that foot off the ground almost once per minute," she said in the statement. "During the immobilization, we did multiple treatments that included hoof trims, stem cell therapy and other medications. "Since then, Mahali is no longer constantly lifting his left front leg off the ground and has resumed cooperating for hoof care. A few weeks ago, he returned to life with his herd, including yard access. On the thermogram, the marked inflammation up the leg has mostly resolved."
Twiga, a 14-year-old female giraffe with advanced arthritis and osteoporosis in her feet, was fitted with custom shoes with the help of farriers Steve Foxworth and Chris Niclas of the Equine Lameness Prevention Organization.
"We've had Twiga on medicine to help reverse her osteoporosis, but we wanted to do more to protect her feet. So with the help of the farriers, we gave her 'giraffe sneakers' to help give her some extra cushion," Dadone said in a written statement.
The giraffe's behavior was immediately changed - "Twiga instantly shifted her weight off of her right foot, indicating she was comfortable and her pain had considerably lessened" - but she will likely wear the shoes for about six more weeks, the zoo said.
Giraffes' size can make them more susceptible to issues like arthritis and osteoporosis. "Like all animals, these issues are exacerbated as they age," according to the zoo news release.
The zoo has a herd of 17 giraffes, including a newborn in April. The calf, a girl, was the 199th to be born in the 63-year history of the zoo's breeding program.
Giraffes' status was recently changed from "least concern" to "vulnerable" by the International Union for Conservation of Nature because the population in the wild has decreased by 40 percent in the last 30 years, the zoo said.
-
Contact Ellie Mulder: 636-0198
Twitter: @lemarie
Read this article:
Cheyenne Mountain Zoo makes medical history with 'giraffe sneakers,' stem cell treatments - Colorado Springs Gazette
Twiga, a 14-year-old female giraffe with advanced arthritis and osteoporosis in her feet, was fitted with custom shoes. (Photo courtesy of Cheyenne Mountain Zoo.)
Two medical breakthroughs have helped heal two giraffes at Cheyenne Mountain Zoo in recent weeks, the zoo announced Wednesday.
Mahali, a 14-year-old male giraffe who suffered from chronic lameness and had not been moving well, is believed to be the first in the world to be injected with stem cells grown from giraffe blood, according to a news release from the zoo.
Stem cell therapy was chosen in the efforts led by Dr. Liza Dadone, the zoo's head veterinarian, because it has proven to repair damaged tissue. Staff at Colorado State University's James L. Voss Veterinary Teaching Hospital in Fort Collins helped with the treatment.
Nearly a month after the procedure, when Mahali was injected with about 100 million stem cells, thermographic images of the giraffe's front legs show "a considerable decline" in inflammation in his front left leg, the leg that had been giving him trouble, the zoo said.
"This is meaningful to us not only because it is the first time a giraffe has been treated with stem cells, but especially because it is bringing Mahali some arthritis relief and could help other giraffes in the near future," Dadone said in a written statement.
Dadone said it's not clear whether the successful results are due only to the stem cell treatment or a combination of treatments.
"Prior to the procedure, he was favoring his left front leg and would lift that foot off the ground almost once per minute," she said in the statement. "During the immobilization, we did multiple treatments that included hoof trims, stem cell therapy and other medications. Since then, Mahali is no longer constantly lifting his left front leg off the ground and has resumed cooperating for hoof care. A few weeks ago, he returned to life with his herd, including yard access. On the thermogram, the marked inflammation up the leg has mostly resolved."
Twiga, a 14-year-old female giraffe with advanced arthritis and osteoporosis in her feet, was fitted with custom shoes with the help of farriers Steve Foxworth and Chris Niclas of the Equine Lameness Prevention Organization.
"We've had Twiga on medicine to help reverse her osteoporosis, but we wanted to do more to protect her feet. So with the help of the farriers, we gave her 'giraffe sneakers' to help give her some extra cushion," Dadone said in a written statement.
The giraffe's behavior was immediately changed - "Twiga instantly shifted her weight off of her right foot, indicating she was comfortable and her pain had considerably lessened" - but she will likely wear the shoes for about six more weeks, the zoo said.
Giraffes' size can make them more susceptible to issues like arthritis and osteoporosis. "Like all animals, these issues are exacerbated as they age," according to the zoo news release.
The zoo has a herd of 17 giraffes, including a newborn in April. The calf, a girl, was the 199th to be born in the 63-year history of the zoo's breeding program.
Giraffes' status was recently changed from "least concern" to "vulnerable" by the International Union for Conservation of Nature because the population in the wild has decreased by 40 percent in the last 30 years, the zoo said.
-
Contact Ellie Mulder: 636-0198
Twitter: @lemarie
More here:
'Sneakers,' stem cells help heal Cheyenne Mountain Zoo's giraffes - Colorado Springs Gazette
Recently, a hospital used the world's most advanced cell immunotherapy (CAR-T) treatment to treat a patient with advanced malignant lymphoma. Two months after transfusion, most of the patient's body mass disappeared, and relevant indicators returned to normal, marking the success of treatment.
The patient was diagnosed two years ago with the diffuse large B-cell lymphoma (non-germinal center origin, ). She had been given multiple R-CHOP, EPOCH, MINE, GDP, DICE, CHOPE and other first-line or second-line chemotherapy, but the condition control is not ideal. PET-CT showed that on tonsil, bilateral neck, supraclavicular area, bilateral axillary, hilar, mediastinal, retroperitoneal area, pelvic and bilateral inguinal, there were multiple lymph nodes. Glucose metabolism was significantly increased, suggesting a wide range of tumor violations. The prognosis is very poor. The conventional treatment of the patients has no obvious effect, and the patients family members placed the last line of hope for lymphoma CAR-T cell therapy. Two months ago, the patient received autologous CD19 CAR-T cells, and a lighter cytokine storm appeared after transfusion. Two months of transfused cells, PET-CT showed that multiple mass had disappeared, and the patient reached a complete remission.
Lymphoma is a common type of malignant blood tumor, and diffuse large mature B-cell neoplasms are the most common type of non-Hodgkin lymphomas. Conventional chemotherapy can make about 50% of patients with lymphoma get long-term survival. New drugs in recent years, such as anti-CD20 monoclonal antibody, improved the prognosis of some patients with poor prognosis. But some patients with poor efficacy of chemotherapy is easy to relapse even if the application of autologous hematopoietic stem cell transplantation is used. CAR-T technology is currently the world's latest tumor treatment technology. The existing data confirms that CAR-T has a good effect for a variety of refractory and recurrent hematological malignancies, such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, etc. Approximately 40-80% of refractory and recurrent non-Hodgkin's lymphoma patients receive efficacy after receiving CAR-T treatment.
The success of CAR-T treatment for lymphoma will further promote the process of cell immunotherapy research.
Media Contact Company Name: CAR-T Contact Person: Bella Smith Email: marketing@creative-biolabs.com Phone: 6316197922 Address:45-1 Ramsey Road City: Shirley State: NY Country: United States Website: http://www.creative-biolabs.com/car-t/
See the original post:
CAR-T Cells from Creative Biolabs Help in the Treatment of Advanced Malignant Lymphoma - Digital Journal
As the exclusive licensee for veterinary applications of this technology, Zander Therapeutics anticipates a crossover effect for canines with cancer and autoimmune disorders. Because canine DNA is close to human DNA structure, it is believed that advancements by Regen BioPharma will directly impact advancements for Zander Therapeutics in developing small molecule therapies for canine cancer and autoimmune disorders in dogs.
The NR2F6 nuclear receptor has been identified as a potentially extremely important immune cell inhibitor and cancer stem cell differentiator. Molecules which function as immune cell inhibitors are called "immune checkpoints" and basically act as an "on or off switch" to an immune response. Cancer cells sometimes find ways to use these checkpoints to avoid being attacked by the immune system - therefore therapies that target these checkpoints demonstrate tremendous potential as cancer treatments.
The NR2F6 program at Zander Therapeutics is focused on identifying antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a dog's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"In addition to the data we received on medicinal chemistry optimization, Zander Therapeutics is conducting ex vivo studies using blood samples from dogs. The Company is examining the validity that because dog DNA and human DNA are so close, any human related advancements made by Regen BioPharma should have a positive impact on our canine model for treating dogs with cancer or autoimmune diseases," says David Koos, Ph.D., Chairman & CEO Zander Therapeutics, Inc.
About Zander Therapeutics Inc. and Entest BioMedical Inc.:
Zander Therapeutics is a subsidiary of Entest BioMedical Inc. (OTCPink: ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary applications.
Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc.'s (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (OTCQB: RGBP), Entest BioMedical Inc. (OTCPINK: ENTB) and Zander Therapeutics Inc. (subsidiary of Entest BioMedical Inc.).
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Zander Therapeutics Inc. and Entest BioMedical Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-702-1404 Phone +1-619-330-2328 Fax
http://www.zandertherapeutics.com/
SOURCE Entest BioMedical Inc.
Read the original here:
Entest BioMedical Inc. Subsidiary Zander Therapeutics Discusses Developments in Medicinal Chemistry for Veterinary ... - PR Newswire (press release)
LEXINGTON, Ky (LEX 18) A retired canine with the Lexington Police Department is still a big goofy dog that acts like a puppy, thanks to stem cell transplants, Garik can continue to do so with less pain.
The City of Lexington featured the dog's story on their website.
Officer Brian Burnette said that he is living the dream by getting to be an officer in the canine unit. He told the City of Lexington that after a couple of years of not connecting with one dog, he was switched to Garik the German Shepherd.
As soon as I got him, we could hit the street together. His drive, we just matched perfectly together, he said.
He described the now seven-year-old dog as a big goofy dog that acts like a puppy and enjoys sniffing for little sticks or twigs in the grass.
While Garik is an active, playful dog, in 2016, Burnette began to notice that something was different. Garik was in a lot of pain. His legs would shake while they were out and he would trip. The department thought that Garik might have hip dysplasia, but Garik had developed a degenerative bone spur on his spine, causing him much pain.
Garik retired and Burnette took him home to live a relaxed life, but Burnette was still concerned about the dog's pain.
That's when a Nicholasville-based company came to the rescue.
Dr. Jeff Baker, President and COO of MediVet Biologics offered a free stem cell kit for Garik.
My mom's a cancer survivor. And she's had stem cell transplants. But I had no idea they even did this for dogs, Burnette told the City of Lexington.
During the treatment, stem cells are extracted from Garik's fat tissue and then re-injected into his body. The procedure is done at Woodford Animal Hospital.
Garik has received two stem cell injections so far.
While the therapy won't cure Garik's condition, they say it will relieve his pain significantly.
This isn't the first time MediVet has helped service dogs, they also donated stem cell therapy kits to the dogs that searched Ground Zero and the Pentagon after 9/11.
Read the original:
Retired Lexington Police Department Canine Undergoes Stem Cell Treatment - LEX18 Lexington KY News
TARPON SPRINGS (FOX 13) - Brian Cirillo is concerned about his 4-year-old dog, Cosby's health. Brian and his wife are self-proclaimed suckers for homeless pets and have six adopted dogs.
"He's always the last one to kind of get moving and if he's laying down for a long time he takes a long time to stand up," Brian explained. "He's the only one that's so scared of everything and I'm starting to wonder now if it's because he's in pain."
To diagnose the problem Cosby got a physical exam, x-rays, and blood tests. There's a possibility Cosby could also qualify to get an injection of experimental stem cells into his joint.
"We're looking at taking the miraculous healing capabilities of the body, concentrating it, and then bringing it back to the body and we're not seeing a lot of side effects," veterinarian Dr. Michael Amsberry said.
He owns the St. Francis Pet Care Center. It's one of several sites across the country taking part in a clinical trial testing whether specially-grown stem cells made by animal cell therapies in San Diego, will help arthritis symptoms in dogs.
"Specifically this study is knees, hips, elbows and shoulders, but the most common is hips," he explained.
The cells are grown from umbilical cord blood.
"What they've done is harvested little umbilical cords from C-sections from dogs and they isolate these cells," Dr. Amsberry described. When the cells grow up, researchers are able to culture them into hundreds of millions of cells. This means one sample can treat thousands of dogs. The treatment is free and Dr. Amsberry says he's injected eight dogs so far.
It's an experimental option Brian hopes will work for Cosby.
"If we can try to get ahead of the problem with stem cells and actually cure the problem and he doesn't have to be on a lot of chemicals and medicines his whole life, that would be great," he said.
For more information on the study or to see if your dog could qualify, visit http://petstemcells.org/.
Read the original:
Arthritic pets see improvement from stem cell injections - FOX 13 News, Tampa Bay
Hepatitis C virus: Possible new approach to battling infections Science Daily An international study led by researchers at Monash University' Biomedicine Discovery Institute (BDI) has shone light on the way the Hepatitis C Virus (HCV) hijacks the communication systems in the host cells it infects, uncovering potential new ... |
Originally posted here:
Hepatitis C virus: Possible new approach to battling infections - Science Daily
Technology Networks | Stems Cells Could Help Treat Slipped Discs Technology Networks Great hope has thus been placed on stem cell therapy as practiced by Frank Steffen, neurologist at the Clinic for Small Animal Surgery at the Vetsuisse Faculty of the University of Zurich. Stem cells are multipotent cells that can be differentiated ... |
Read this article:
Stems Cells Could Help Treat Slipped Discs - Technology Networks